FDA OKs new Nexium formulation

Share this article:
AstraZeneca said Tuesday a new formulation of its blockbuster heartburn treatment Nexium has won FDA approval. Like its capsule counterpart, the new delayed-release oral suspension version of Nexium is designed to treat gastroesophageal reflux disease and reduce the risk of non-steroidal anti-inflammatory drug associated stomach ulcers, AstraZeneca said. “Some patients with acid-related diseases have difficulties swallowing their oral medication when it is a solid pill,” said Nexium development leader Doug Levine in a statement. “This new prescription option to swallow an oral suspension of Nexium, or to have it administered via a stomach tube, provides patients with an alternative method of administration.” Nexium was the third best-selling global prescription drug brand for 2005, with sales of $5.7 billion, according to figures from IMS Health. Nexium was also third best in the US prescription drug market during 2005, with sales of $4.2 billion. The new Nexium formulation will be available in the first quarter of 2007, AstraZeneca said.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.